BIO vs NTLA · rev $651.0M vs rev $22.7M
BIO (BIO) versus Intellia Therapeutics Inc (NTLA) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Intellia Therapeutics Inc (NTLA) is a biotechnology company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported NTLA revenue for 2026-06-30 was $22.7M. Net income was -$202.9M. Revenue was up 50.9% from 2026-03-31 to 2026-06-30. NTLA currently screens at market cap $1.19B.
BIO currently screens at market cap $0. NTLA currently screens at market cap $1.19B.
Not investment advice. Open the BIO and NTLA stock pages for the full models.
Not investment advice.